Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Barbara Geller |
Documentos disponibles escritos por este autor (1)
Refinar búsqueda
Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder / Barbara Geller en Annual progress in child psychiatry and child develoment, Año 1993 ([09/11/2020])
[artículo]
Título : Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder Tipo de documento: texto impreso Autores: Barbara Geller, Autor ; Thomas B. Cooper, Autor ; Donna L. Graham, Autor Fecha de publicación: 2020 Artículo en la página: pp. 477-502 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastorno depresivo, Nortriptilina, Evaluación de personalidad Resumen: A random assignment, double-blind, placebo-controlled study of nortriptyline in 50 prepubertal 6- to 12-year-olds with Research Diagnostic Criteria and DSM-III major depressive disorder was performed. The protocol included a 2-week placebo wash-out phase and an 8-week double-blind, placebo-controlled phase with weekly plasma level monitoring. Link: ./index.php?lvl=notice_display&id=25170
in Annual progress in child psychiatry and child develoment > Año 1993 [09/11/2020] . - pp. 477-502[artículo] Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder [texto impreso] / Barbara Geller, Autor ; Thomas B. Cooper, Autor ; Donna L. Graham, Autor . - 2020 . - pp. 477-502.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Annual progress in child psychiatry and child develoment > Año 1993 [09/11/2020] . - pp. 477-502
Palabras clave: Trastorno depresivo, Nortriptilina, Evaluación de personalidad Resumen: A random assignment, double-blind, placebo-controlled study of nortriptyline in 50 prepubertal 6- to 12-year-olds with Research Diagnostic Criteria and DSM-III major depressive disorder was performed. The protocol included a 2-week placebo wash-out phase and an 8-week double-blind, placebo-controlled phase with weekly plasma level monitoring. Link: ./index.php?lvl=notice_display&id=25170